期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Efficacy of Saam acupuncture treatment on improvement of immune cell numbers in cancer patients:a pilot study 被引量:11
1
作者 Dae-Joon Kim Seong-Hoon Park +4 位作者 Jung-Chul Seo Kyung Soon Kim Ki Cheul Sohn Im Hee Shin hun mo ryoo 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2014年第5期550-554,共5页
OBJECTIVE: To collect preliminary data on the effects of Saam acupuncture with regard to the immunity in cancer patients.METHODS: Ten cancer patients were analyzed for improvements in immunity. Acupuncture was applied... OBJECTIVE: To collect preliminary data on the effects of Saam acupuncture with regard to the immunity in cancer patients.METHODS: Ten cancer patients were analyzed for improvements in immunity. Acupuncture was applied at the 5 acupuncture points, Jingqu(LU 8), Zutonggu(BL 66), Yanggu(SI 5), Yangchi(TE 4), and Zhongwan(CV 12) for 2 weeks with 4 sessions. We assessed the effect of Korean Saam acupuncture on the immune system in cancer patients by measuring particular blood cell subsets, including CD3 +,CD4+, CD8+, CD19+, and CD56+ cells, as well as total white blood cell count, absolute neutrophil count, and fatigue score. The measurement was performed before and after acupuncture and at a 2-week follow-up.RESULTS: There was a statistically significant increase in the number of CD3+(P=0.023) and CD8+ cells(P<0.001) and T-cell subsets, as well as a decrease in the fatigue severity scale(FSS) score(P=0.001) after Saam acupuncture using the 5 acupoints.CONCLUSION: Acupuncture may improve the immune system by increasing the counts of a few immune cells and relieve fatigue in cancer patients by decreasing FSS scores. Although this was a non-controlled study, it constitutes preliminary research investigating the potential effects of Saam acupuncture in increasing the counts of several immune cells in cancer patients. 展开更多
关键词 ACUPUNCTURE Leukocyte count Neutro-phils Fatigue severity scale Pilot projects
原文传递
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis
2
作者 Jun Ho Yi Seok Jin Kim +18 位作者 Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok Hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung Kim Dae Sik Kim Ji Hyun Lee Sung Yong Oh hun mo ryoo Hyo Jung Kim Won Seog Kim 《Cancer Communications》 SCIE 2021年第3期275-278,共4页
Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustin... Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease. 展开更多
关键词 PATIENTS RELAPSE LYMPHOMA
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部